Preclinical testing of a novel non-hormonal intravaginal ring to prevent pregnancy and sexually transmitted infections
新型非激素阴道环预防怀孕和性传播感染的临床前测试
基本信息
- 批准号:10700070
- 负责人:
- 金额:$ 40.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-22 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:AIDS preventionAdherenceAdvanced DevelopmentAdvisory CommitteesAndrologyAnimalsAnti-Bacterial AgentsAnti-Infective AgentsAreaBacteriaBacterial VaginosisBiological Response ModifiersBiologyBloodCalibrationCellsCervicalCervix MucusChemicalsChlamydiaClinicalClinical TrialsCollaborationsContraceptive AgentsContraceptive methodsCopperCopper SulfateDataDevelopmentDoseDrug KineticsEvaluationFemale CondomsFormulationGoalsGonorrheaHIVHIV-1HealthHistologyHormonalHumanHuman Herpesvirus 2ImmuneIn VitroIonsLactic acidLactobacillusLeadMacaca mulattaMale CondomsMethodsMusOryctolagus cuniculusPenetrationPharmaceutical PreparationsPharmacologic SubstancePopulationPositioning AttributePreclinical TestingPregnancyPreventionProdrugsQualifyingResearchResearch PersonnelResearch Project GrantsSTI preventionSafetySeminal PlasmaSexually Transmitted DiseasesSheepSimplexvirusTechnologyTestingToxic effectUnited States Food and Drug AdministrationUniversitiesVaginaVaginal RingViralWomanZinc Acetateantimicrobialcell motilitycervicovaginalcollegecombatcontraceptive efficacycostdesigndosageefficacy testinghormonal contraceptionimprovedin vitro activityin vitro testingin vivoin vivo evaluationinnovationlead candidatemicrobiotamultidisciplinarynovelpre-Investigational New Drug meetingpre-clinicalpregnancy preventionpreventproduct developmentprototypepublic health interventionrRNA Genesresearch and developmentsafety assessmentside effectskillssperm celltechnology developmenttranscriptometranscriptome sequencingunintended pregnancyuptakevaginal fluidvaginal microbiota
项目摘要
PROJECT II – ABSTRACT
Globally, 85 million unintended pregnancies occur per year and more than 1 million sexually transmitted
infections (STIs) are acquired every day, emphasizing a clear unmet need for improved contraception and
protection against STIs. Currently available multipurpose prevention technology (MPT) products for women that
combine contraception and anti-HIV/STI prevention are limited to female and male condoms. The contraception
options within MPTs are dominated by hormonal methods. Given the side effects of hormonal contraceptives
and high rates of many STIs, non-hormonal MPT may be appealing for some women and would be a new and
critically needed area of innovation in the MPT development pipeline to better provide a range of options and
increase uptake. In collaboration with several university partners, the Population Council is developing a novel
30-day intravaginal ring (IVR) to prevent unintended pregnancy and STIs (herpes simplex virus, gonorrhea,
chlamydia, and possibly HIV) while promoting vaginal health. The IVR releases Copper, Zinc acetate (ZA) and
Lactide (CZL-IVR). The overarching goal of Project 2 is to complete preclinical testing for this unique
product to determine the target API release and the overall safety and efficacy of our CZL-IVR. This project
will define the critical clinical indications that we will pursue and the optimal dosing for this novel triple-API
combination. The CZL-IVR will utilize three APIs, enabling Project 2 to calibrate dosages to minimize toxicity and
maximize efficacy. The APIs are low-cost, easy-to-obtain chemicals with existing safety profiles, which will
mitigate the regulatory challenges associated with products containing multiple APIs. Project 2 includes
contraceptive and anti-STI activity testing in vitro (Aim 1) and in vivo in mice and rabbits (Aim 2);
pharmacokinetics (PK) and local toxicity studies in vivo in sheep (Aim 3); and in-depth safety/PK and anti-
bacterial vaginosis effect assessments (vaginal microbiota, transcriptome and immune mediators) in vivo in
rhesus macaques (Aim 4). This project will be closely coordinated with Project 1 to inform IVR loading and
selection of the lead IVR. Our multidisciplinary collaborative team is uniquely qualified to advance the
development of this novel MPT IVR. The CZL-IVR will address a critical gap in the non-hormonal contraceptive
landscape, fill a niche that users want and deliver an important public health intervention. While pregnancy
prevention will be the primary indication defining the regulatory approach for our CZL-IVR, the triple-active API
strategy offers broader antimicrobial benefits, distinguishes our TPP from others under development, and opens
avenues for pursuing regulatory approval for indications beyond contraception. While our ideal product will
provide protection from a broad range of STIs, the specific secondary indications we chose to pursue will be
based on our preclinical data, regulatory considerations, and advice from our advisory committees.
项目二-摘要
在全球范围内,每年发生8500万次意外怀孕,100多万次性传播
每天都会发生感染(STI),这凸显了人们对改进避孕措施和
预防性传播感染。目前可供妇女使用的多用途预防技术产品,
联合收割机和抗艾滋病毒/性传播感染的预防仅限于女用和男用避孕套。避孕
MPT中的选择主要是激素方法。考虑到激素避孕药的副作用
和许多性传播感染的高发病率,非激素MPT可能对一些妇女有吸引力,
MPT开发管道中急需的创新领域,以更好地提供一系列选择,
增加摄取。人口理事会与几个大学伙伴合作,正在编写一本小说,
30-日阴道环(IVR),以防止意外怀孕和性传播感染(单纯疱疹病毒,淋病,
衣原体,可能还有艾滋病毒),同时促进阴道健康。IVR释放铜、醋酸锌(ZA)和
丙交酯(CZL-IVR)。项目2的总体目标是完成这种独特的临床前测试。
产品,以确定目标API释放和我们的CZL-IVR的总体安全性和有效性。这个项目
将确定我们将追求的关键临床适应症和这种新型三联API的最佳剂量
组合. CZL IVR将使用三种API,使项目2能够校准剂量以最大限度地减少毒性,
最大化功效。原料药是低成本,易于获得的化学品,具有现有的安全特性,
减轻与含有多种API的产品相关的监管挑战。项目2包括
体外(目标1)和小鼠和家兔体内(目标2)避孕和抗STI活性试验;
绵羊体内药代动力学(PK)和局部毒性研究(目标3);以及深入的安全性/PK和抗-
体内细菌性阴道病效应评估(阴道微生物群、转录组和免疫介质)
恒河猴(Aim 4)。该项目将与项目1密切协调,以通知IVR加载,
选择领导IVR。我们的多学科合作团队是唯一有资格推动
开发这种新型MPT IVR。CZL-IVR将解决非激素避孕药的关键差距
景观,填补用户想要的利基市场,并提供重要的公共卫生干预措施。虽然妊娠
预防将是定义我们的CZL-IVR(三效API)监管方法的主要适应症
该战略提供了更广泛的抗菌益处,将我们的TPP与其他正在开发的TPP区分开来,并开放
寻求监管机构批准避孕以外的适应症的途径。虽然我们的理想产品将
提供保护免受广泛的性传播感染,我们选择追求的具体次要适应症将是
基于我们的临床前数据、监管考虑和咨询委员会的建议。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Natalia Teleshova其他文献
Natalia Teleshova的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Natalia Teleshova', 18)}}的其他基金
Preclinical testing of a novel non-hormonal intravaginal ring to prevent pregnancy and sexually transmitted infections
新型非激素阴道环预防怀孕和性传播感染的临床前测试
- 批准号:
10493315 - 财政年份:2021
- 资助金额:
$ 40.27万 - 项目类别:
Preclinical testing of a novel non-hormonal intravaginal ring to prevent pregnancy and sexually transmitted infections
新型非激素阴道环预防怀孕和性传播感染的临床前测试
- 批准号:
10324917 - 财政年份:2021
- 资助金额:
$ 40.27万 - 项目类别:
Novel pre-coital, non-hormonal multipurpose prevention technology (MPT)
新型性交前非激素多用途预防技术 (MPT)
- 批准号:
9925495 - 财政年份:2020
- 资助金额:
$ 40.27万 - 项目类别:
Effect of sex hormones on HIV infection of cervical and rectal mucosal tissue
性激素对宫颈及直肠粘膜组织HIV感染的影响
- 批准号:
8588219 - 财政年份:2013
- 资助金额:
$ 40.27万 - 项目类别:
Effect of sex hormones on HIV infection of cervical and rectal mucosal tissue
性激素对宫颈及直肠粘膜组织HIV感染的影响
- 批准号:
9316522 - 财政年份:2013
- 资助金额:
$ 40.27万 - 项目类别:
Effect of sex hormones on HIV infection of cervical and rectal mucosal tissue
性激素对宫颈及直肠粘膜组织HIV感染的影响
- 批准号:
8708757 - 财政年份:2013
- 资助金额:
$ 40.27万 - 项目类别:
MACAQUE EXPLANT MODEL FOR MICROBICIDE TESTING
用于杀菌剂测试的猕猴外植体模型
- 批准号:
8358166 - 财政年份:2011
- 资助金额:
$ 40.27万 - 项目类别:
相似海外基金
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 40.27万 - 项目类别:
Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 40.27万 - 项目类别:
Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 40.27万 - 项目类别:
Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 40.27万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 40.27万 - 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 40.27万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 40.27万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 40.27万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 40.27万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 40.27万 - 项目类别:
Fellowship Programs